ProNAi Therapeutics

General Information

We are a clinical-stage oncology company pioneering a novel class of therapeutics based on our proprietary DNA interference (DNAi) technology platform. Our vision is to be the leader in developing and commercializing a portfolio of DNAi-based therapies to deliver extraordinary therapeutic outcomes that dramatically change patients’ lives. The core of our scientific expertise is our understanding of DNAi oligonucleotides, which are rationally designed DNA sequences that modulate the transcription of oncogenes known to be involved in cancer cell survival and proliferation. Our lead DNAi product candidate, PNT2258, targets BCL2, a widely overexpressed oncogene that is an important gatekeeper of the programmed cell death process known as apoptosis and has been linked to many forms of cancer.

Employees: 40
Founded: 2003
Contact Information
Address 2150 – 885 West Georgia Street, Vancouver, British Columbia, Canada V6C 3E8
Phone Number (734) 233-3966
Web Address
View Prospectus: ProNAi Therapeutics
Financial Information
Market Cap $490.1mil
Revenues $0.0 mil (last 12 months)
Net Income $-87.9 mil (last 12 months)
IPO Profile
Symbol DNAI
Exchange NASDAQ
Shares (millions): 8.1
Price range $17.00 - $17.00
Est. $ Volume $137.7 mil
Manager / Joint Managers Jefferies/ BofA Merrill Lynch
CO-Managers Wedbush PacGrow/ SunTrust Robinson Humphrey
Expected To Trade: 7/16/2015
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change